ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulato…
Biotechnology
US, San Diego [HQ]
IBRX/Financial Reporting
Income Statements
10 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | 2.00 | - - | - - | - - | - - | |
|
EPS
|
-0.02 | -0.83 | -0.37 | -0.30 | -0.30 | -0.42 | -0.59 | -0.90 | -1.04 | -1.15 | |
| Diluted in mil. | -0.02 | -0.83 | -0.37 | -0.30 | -0.30 | -0.42 | -0.59 | -0.90 | -1.04 | -1.15 | |
|
Profit
|
- - | - - | - - | - - | - - | -6.00 | -8.00 | - - | -23.00 | -17.00 | |
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | -309.26 | -1,411.90 | 100.00 | -9,980.00 | -2,876.21 | |
| Pre Tax | -6.00 | -237.00 | -121.00 | -96.00 | -96.00 | -160.00 | -226.00 | -349.00 | -417.00 | -583.00 | |
| Profit Margin | -969.11 | -100,498.73 | -275,865.91 | -215,368.89 | -205,806.38 | -7,278.07 | -37,360.83 | -37,456.00 | -173,869.17 | -93,873.31 | |
| ETR | -0.02 | 0.13 | 0.47 | 0.51 | 0.52 | 0.07 | 0.82 | - - | -0.01 | 0.01 | |
| Net | -6.00 | -236.00 | -120.00 | -96.00 | -96.00 | -160.00 | -224.00 | -349.00 | -417.00 | -583.00 | |
| Profit Margin | -969.27 | -100,371.19 | -274,565.91 | -214,273.33 | -204,736.17 | -7,273.30 | -37,055.70 | -37,456.96 | -173,883.33 | -93,761.41 | |
| EBITDA | -6.00 | -235.00 | -117.00 | -90.00 | -86.00 | -139.00 | -195.00 | -316.00 | -343.00 | -342.00 | |
| EBITDA Margin | -949.14 | -99,875.00 | -267,518.18 | -201,626.67 | -184,555.32 | -6,356.77 | -32,252.56 | -33,865.52 | -143,324.17 | -55,120.90 | |
| Operating Income | -6.00 | -237.00 | -121.00 | -96.00 | -96.00 | -156.00 | -220.00 | -330.00 | -351.00 | -361.00 | |
| Operating Margin | -969.11 | -100,498.73 | -275,715.91 | -213,995.56 | -204,885.11 | -7,095.87 | -36,509.09 | -35,361.88 | -146,374.17 | -58,097.11 | |
| Interest Income | - - | - - | - - | - - | - - | 2.00 | 1.00 | - - | 2.00 | 2.00 | |
| Loss | -6.00 | -239.00 | -124.00 | -99.00 | -98.00 | -158.00 | -210.00 | -331.00 | -350.00 | -361.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | -9.00 | -9.00 | - - | -24.00 | -18.00 | |
|
Operating Expenses
|
-5.00 | -239.00 | -124.00 | -99.00 | -98.00 | -158.00 | -210.00 | -331.00 | -350.00 | -343.00 | |
| R&D | -1.00 | -11.00 | -29.00 | -42.00 | -55.00 | -111.00 | -139.00 | -195.00 | -248.00 | -213.00 | |
| G&A | -4.00 | -227.00 | -95.00 | -57.00 | -42.00 | - - | - - | - - | - - | - - | |
| SG&A | -4.00 | -227.00 | -95.00 | -57.00 | -42.00 | -46.00 | -71.00 | -135.00 | -102.00 | -129.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | -1.00 | -3.00 | -5.00 | -9.00 | -14.00 | -12.00 | -14.00 | -18.00 | -18.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | -5.00 | -9.00 | -14.00 | -63.00 | -129.00 | |
| Other Expenses | - - | -1.00 | - - | - - | - - | -4.00 | -5.00 | -19.00 | -65.00 | -222.00 | |
|
WA Shares Outstanding
|
315.00 | 286.00 | 327.00 | 322.00 | 316.00 | 383.00 | 383.00 | 389.00 | 399.00 | 508.00 | |
| Diluted | 315.00 | 286.00 | 327.00 | 322.00 | 316.00 | 383.00 | 383.00 | 389.00 | 399.00 | 508.00 |